Wide Ranks

ARVN

Arvinas, Inc.

25.98

Top Statistics
Market Cap 1 B Forward PE -5.54 Revenue Growth 196.00 %
Current Ratio 4.17 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -191.56 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -1.89 Enterprise / Revenue 4.13 Price To Sales Trailing12 Months 11.08
Profitability
Profit Margins -191.56 % Operating Margins -58.89 %
Balance Sheet
Total Cash 1 B Total Cash Per Share 16.32 Total Debt 1 M
Total Debt To Equity 0.2560 Current Ratio 4.17 Book Value Per Share 8.53
All Measures
Short Ratio 1366.00 % Message Board Id finmb_243040896 Shares Short Prior Month 9 M
Return On Equity -0.5916 City New Haven Uuid 5ab3d208-4f36-3880-916e-a34548e61b36
Previous Close 24.48 First Trade Date Epoch Utc 1 B Book Value 8.53
Beta 1.97 Total Debt 1 M Volume 501910
Price To Book 3.05 Fifty Two Week Low 21.17 Total Cash Per Share 16.32
Total Revenue 161 M Shares Short Previous Month Date 1 B Target Median Price 60.00
Audit Risk 2 Max Age 86400 Recommendation Mean 1.43
Sand P52 Week Change 0.3133 Operating Margins -58.89 % Target Mean Price 62.95
Net Income To Common -308600000 Short Percent Of Float 0.1265 Implied Shares Outstanding 68 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 734200
Average Volume10days 734200 Total Cash 1 B Next Fiscal Year End 1 B
Revenue Per Share 2.33 Held Percent Insiders 0.0722 Ebitda Margins -218.87 %
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Share Holder Rights Risk 9 Regular Market Previous Close 24.48 Target Low Price 28.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 25.65 Open 24.50
Free Cashflow -170112496 State CT Dividend Yield 0.00 %
Return On Assets -0.2007 Time Zone Short Name EST Board Risk 9
Trailing Eps -4.79 Day Low 24.38 Address1 5 Science Park
Shares Outstanding 68 M Compensation Risk 8 Price Hint 2
Target High Price 110.00 Website https://www.arvinas.com 52 Week Change 0.1825
Average Volume 568731 Forward Eps -4.66 Recommendation Key strong_buy
Compensation As Of Epoch Date 1 B Quick Ratio 411.90 % Is_sp_500 False
Regular Market Day High 26.30 Profit Margins -191.56 % Debt To Equity 0.2560
Fifty Two Week High 53.08 Day High 26.30 Shares Short 8 M
Regular Market Open 24.50 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue 4.13 Revenue Growth 196.00 % Shares Percent Shares Out 0.1243
Operating Cashflow -258300000 Currency USD Time Zone Full Name America/New_York
Market Cap 1 B Is_nasdaq_100 False Zip 06511
Quote Type EQUITY Industry Biotechnology Long Name Arvinas, Inc.
Overall Risk 8 Regular Market Day Low 24.38 Held Percent Institutions 1.08
Current Price 25.98 Address2 395 Winchester Avenue Enterprise To Ebitda -1.89
Financial Currency USD Current Ratio 4.17 Gross Margins 100.00 %
Industry Disp Biotechnology Number Of Analyst Opinions 19 Country United States
Float Shares 57 M Two Hundred Day Average 30.92 Governance Epoch Date 1 B
Enterprise Value 665 M Price To Sales Trailing12 Months 11.08 Forward PE -5.54
Regular Market Volume 501910 Ebitda -352600000 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.

The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.

Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial.

Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F.

Hoffman-La Roche Ltd.

, Carrick Therapeutics Limited, and Bayer AG.

The company was founded in 2013 and is based in New Haven, Connecticut.